SLE - Systemic Lupus Erythematosus
- Fibrosis / scarring
- Vasospasm (including Reynaud’s Syndrome)
- Vascular Thrombosis
- Prevalence is roughly 1 in 4000
- About 10x more common in women!
- 2-3x more common in Indian Asians than Caucasians
- 5x more common in black Africans than in Caucasians
- Can present at any age
- Peak incidence is between 25-35
- Second peak of incidence is between 50-60
- Strong genetic disposition
- Family members 50x more likely to have the disease than members of the general population
- UV light exposure thought to increase the risk
- Chlorpromazine, hydralazine, isoniazid
Photosensitive rash – can occur anywhere on the body, but typically seen on the face – as this area is most likely to be exposed to the sun!
- General malaise
- Low-grade fever
- Weight loss
- Mucosal ulceration – particularly in the mouth
- Nail edge infarcts
- Splinter haemorrhages
Arthritis - Usually:
- Small joints
- The arthritis is non-erosive, and thus the joint is permanently damadged, but there may be ligament damage, which can cause deformities similar to rheumatoid arthritis. However, unlike in RA, the deformities are reducible, and they should not affect joint function – e.g. the patient should be able to make a fist.
- Nephrosis – anti DNA antibodies are toxic to the kidney
Nervous system involvement
According to the American College of Rheumatology (ACR), for a patient to be diagnosed with SLE, they must fulfil 4 of the following 11 criteria:
Discoid Rash – a round or oval rash seen on areas of skin exposed to sunlight
- Proteinuria (>0.5g/day)
- Red cell casts in urine
- Haemolyitc anaemia
- Antibodies to double stranded DNA
- Anti-Sm antibodies
- Urine dipstick – increased protein, red cell casts
- Blood – anaemia, thrombocytopenia, leukopenia, lymphpaenia, raised ESR and CRP.
- ANA testing – positive in 90% of patients. Concentration of antibodies does not reflect the severity of the disease.
- Antibodies to doublestranded DNA (dsDNA)– highly specific for SLE – but only present in 60% of cases. In some patients, the concentration of the antibodies may reflect the severity of the underlying disease
- Increased incidence of atherosclerotic disease
- Increased risk of thrombosis
Increased risk of infection
- Usually due to immunosuppressive treatment of the disorder
- Mild disease - No specific therapies may be needed. The patient may be able to use topical NSAID therapy on the affected areas, and make lifestyle changes (E.g. avoiding the sun), and may otherwise need no further therapy
- Mild to moderate disease - Treatment is essentially similar to RA. Patients may use disease modifying drugs (e.g. methotrexate, leflunomide, azathiaprin, hydroxychlorequine), and use steroid injections for specific flare ups.
- Organ involvement - Treat the organ complications as separate entities with specific treatments
- Neurological disorders - Also treated with specific therapies, e.g. anticonvulsants